Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects

Leigh P. Brody; Meliz Sahuri-Arisoylu; James R. Parkinson; Harry G. Parkes; Po Wah So; Nabil Hajji; Elouise Thomas; Gary S. Frost; Andrew D. Miller; Jimmy D. Bell

doi:10.2147/IJN.S135968

Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects

Leigh P. Brody, Meliz Sahuri-Arisoylu, James R. Parkinson, Harry G. Parkes, Po Wah So, Nabil Hajji, Elouise Thomas, Gary S. Frost, Andrew D. Miller, Jimmy D. Bell^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

Metabolic reengineering using nanoparticle delivery represents an innovative therapeutic approach to normalizing the deregulation of cellular metabolism underlying many diseases, including cancer. Here, we demonstrated a unique and novel application to the treatment of malignancy using a short-chain fatty acid (SCFA)-encapsulated lipid-based delivery system – liposome-encapsulated acetate nanoparticles for cancer applications (LITA-CAN). We assessed chronic in vivo administration of our nanoparticle in three separate murine models of colorectal cancer. We demonstrated a substantial reduction in tumor growth in the xenograft model of colorectal cancer cell lines HT-29, HCT-116 p53+/+ and HCT-116 p53-/-. Nanoparticle-induced reductions in histone deacetylase gene expression indicated a potential mechanism for these anti-proliferative effects. Together, these results indicated that LITA-CAN could be used as an effective direct or adjunct therapy to treat malignant transformation in vivo.

Original language	English
Pages (from-to)	6677-6685
Number of pages	9
Journal	International Journal of Nanomedicine
Volume	12
DOIs	https://doi.org/10.2147/IJN.S135968
Publication status	Published - 8 Sept 2017
Externally published	Yes

Keywords

Cancer
Epigenetics
Lipid-based nanoparticles
Liposomes
Short-chain fatty acids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/IJN.S135968

Cite this

Brody, L. P., Sahuri-Arisoylu, M., Parkinson, J. R., Parkes, H. G., So, P. W., Hajji, N., Thomas, E., Frost, G. S., Miller, A. D., & Bell, J. D. (2017). Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects. International Journal of Nanomedicine, 12, 6677-6685. https://doi.org/10.2147/IJN.S135968

@article{959696ea2fe741a9885df4b96ca3e988,

title = "Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects",

abstract = "Metabolic reengineering using nanoparticle delivery represents an innovative therapeutic approach to normalizing the deregulation of cellular metabolism underlying many diseases, including cancer. Here, we demonstrated a unique and novel application to the treatment of malignancy using a short-chain fatty acid (SCFA)-encapsulated lipid-based delivery system – liposome-encapsulated acetate nanoparticles for cancer applications (LITA-CAN). We assessed chronic in vivo administration of our nanoparticle in three separate murine models of colorectal cancer. We demonstrated a substantial reduction in tumor growth in the xenograft model of colorectal cancer cell lines HT-29, HCT-116 p53+/+ and HCT-116 p53-/-. Nanoparticle-induced reductions in histone deacetylase gene expression indicated a potential mechanism for these anti-proliferative effects. Together, these results indicated that LITA-CAN could be used as an effective direct or adjunct therapy to treat malignant transformation in vivo.",

keywords = "Cancer, Epigenetics, Lipid-based nanoparticles, Liposomes, Short-chain fatty acids",

author = "Brody, {Leigh P.} and Meliz Sahuri-Arisoylu and Parkinson, {James R.} and Parkes, {Harry G.} and So, {Po Wah} and Nabil Hajji and Elouise Thomas and Frost, {Gary S.} and Miller, {Andrew D.} and Bell, {Jimmy D.}",

note = "Publisher Copyright: {\textcopyright} 2017 Brody et al.",

year = "2017",

month = sep,

day = "8",

doi = "10.2147/IJN.S135968",

language = "English",

volume = "12",

pages = "6677--6685",

journal = "International Journal of Nanomedicine",

issn = "1176-9114",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects

AU - Brody, Leigh P.

AU - Sahuri-Arisoylu, Meliz

AU - Parkinson, James R.

AU - Parkes, Harry G.

AU - So, Po Wah

AU - Hajji, Nabil

AU - Thomas, Elouise

AU - Frost, Gary S.

AU - Miller, Andrew D.

AU - Bell, Jimmy D.

PY - 2017/9/8

Y1 - 2017/9/8

N2 - Metabolic reengineering using nanoparticle delivery represents an innovative therapeutic approach to normalizing the deregulation of cellular metabolism underlying many diseases, including cancer. Here, we demonstrated a unique and novel application to the treatment of malignancy using a short-chain fatty acid (SCFA)-encapsulated lipid-based delivery system – liposome-encapsulated acetate nanoparticles for cancer applications (LITA-CAN). We assessed chronic in vivo administration of our nanoparticle in three separate murine models of colorectal cancer. We demonstrated a substantial reduction in tumor growth in the xenograft model of colorectal cancer cell lines HT-29, HCT-116 p53+/+ and HCT-116 p53-/-. Nanoparticle-induced reductions in histone deacetylase gene expression indicated a potential mechanism for these anti-proliferative effects. Together, these results indicated that LITA-CAN could be used as an effective direct or adjunct therapy to treat malignant transformation in vivo.

AB - Metabolic reengineering using nanoparticle delivery represents an innovative therapeutic approach to normalizing the deregulation of cellular metabolism underlying many diseases, including cancer. Here, we demonstrated a unique and novel application to the treatment of malignancy using a short-chain fatty acid (SCFA)-encapsulated lipid-based delivery system – liposome-encapsulated acetate nanoparticles for cancer applications (LITA-CAN). We assessed chronic in vivo administration of our nanoparticle in three separate murine models of colorectal cancer. We demonstrated a substantial reduction in tumor growth in the xenograft model of colorectal cancer cell lines HT-29, HCT-116 p53+/+ and HCT-116 p53-/-. Nanoparticle-induced reductions in histone deacetylase gene expression indicated a potential mechanism for these anti-proliferative effects. Together, these results indicated that LITA-CAN could be used as an effective direct or adjunct therapy to treat malignant transformation in vivo.

KW - Cancer

KW - Epigenetics

KW - Lipid-based nanoparticles

KW - Liposomes

KW - Short-chain fatty acids

UR - http://www.scopus.com/inward/record.url?scp=85029375143&partnerID=8YFLogxK

U2 - 10.2147/IJN.S135968

DO - 10.2147/IJN.S135968

M3 - Article

C2 - 28932113

AN - SCOPUS:85029375143

SN - 1176-9114

VL - 12

SP - 6677

EP - 6685

JO - International Journal of Nanomedicine

JF - International Journal of Nanomedicine

ER -

Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this